Takeda Pharmaceutical (NYSE:TAK) Rating Increased to Hold at Zacks Research

Takeda Pharmaceutical (NYSE:TAK) was upgraded by equities researchers at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued on Tuesday,Zacks.com reports.

TAK has been the topic of several other research reports. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Takeda Pharmaceutical in a research report on Monday, December 29th. Morgan Stanley began coverage on Takeda Pharmaceutical in a research report on Tuesday, January 13th. They set an “overweight” rating on the stock. Finally, Wall Street Zen upgraded shares of Takeda Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research note on Saturday, January 31st. One investment analyst has rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold”.

Takeda Pharmaceutical Stock Up 0.8%

Shares of TAK stock opened at $18.22 on Tuesday. Takeda Pharmaceutical has a 52-week low of $12.99 and a 52-week high of $18.82. The firm’s 50-day moving average is $17.11 and its 200-day moving average is $15.42. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.65 and a current ratio of 1.19. The stock has a market cap of $57.98 billion, a price-to-earnings ratio of 75.92 and a beta of 0.01.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings data on Thursday, January 29th. The company reported $0.95 EPS for the quarter, beating the consensus estimate of $0.55 by $0.40. The firm had revenue of $6.75 billion for the quarter, compared to the consensus estimate of $7.81 billion. Takeda Pharmaceutical had a net margin of 2.58% and a return on equity of 10.60%. Sell-side analysts predict that Takeda Pharmaceutical will post 1.64 EPS for the current year.

Institutional Investors Weigh In On Takeda Pharmaceutical

A number of large investors have recently modified their holdings of the business. Capital Research Global Investors raised its stake in Takeda Pharmaceutical by 0.6% during the fourth quarter. Capital Research Global Investors now owns 13,486,772 shares of the company’s stock worth $210,259,000 after acquiring an additional 82,643 shares in the last quarter. UBS Group AG grew its holdings in shares of Takeda Pharmaceutical by 46.4% during the 3rd quarter. UBS Group AG now owns 5,893,969 shares of the company’s stock valued at $86,288,000 after purchasing an additional 1,869,323 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its position in Takeda Pharmaceutical by 100.9% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 5,682,847 shares of the company’s stock worth $88,596,000 after purchasing an additional 2,854,069 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Takeda Pharmaceutical by 15.0% during the first quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock worth $79,120,000 after buying an additional 692,404 shares during the last quarter. Finally, Brandes Investment Partners LP boosted its holdings in shares of Takeda Pharmaceutical by 5.9% during the 2nd quarter. Brandes Investment Partners LP now owns 3,712,278 shares of the company’s stock valued at $57,392,000 after acquiring an additional 208,136 shares in the last quarter. Institutional investors and hedge funds own 9.17% of the company’s stock.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.